3.0.0
383
2024-06-12T18:20:59Z
2024-06-12T18:20:59Z
House
H
HR
2023-01-17
118
[Congressional Record Volume 169, Number 12 (Tuesday, January 17, 2023)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mrs. HARSHBARGER:H.R. 383.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8 of the United States Constitution[Page H244]
- hsif00
Energy and Commerce Committee
House
Standing
  - hsif14
Health Subcommittee
    - Referred to
2023-01-27T19:13:10Z
  - Referred to
2023-01-17T19:02:30Z

- Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
118
4368
HR
2023-09-28
Motion to reconsider laid on the table Agreed to without objection.
23:30:16
  - Related bill
CRS
- 2023-01-27
  - hsif14
Health Subcommittee
1
House committee actions
Referred to the Subcommittee on Health.
Committee
- 2023-01-17
Referred to the House Committee on Energy and Commerce.
IntroReferral
H11100
2
House floor actions
  - hsif00
Energy and Commerce Committee
- 2023-01-17
Introduced in House
IntroReferral
Intro-H
9
Library of Congress
- 2023-01-17
Introduced in House
IntroReferral
1000
9
Library of Congress
- H001086
Rep. Harshbarger, Diana [R-TN-1]
Diana
Harshbarger
R
TN
1
N
- H001082
Rep. Hern, Kevin [R-OK-1]
Kevin
Hern
R
OK
1
2023-01-17
True
- L000564
Rep. Lamborn, Doug [R-CO-5]
Doug
Lamborn
R
CO
5
2023-01-17
True
- B001307
Rep. Baird, James R. [R-IN-4]
James
Baird
R
IN
R.
4
2023-01-17
True
- C001103
Rep. Carter, Earl L. "Buddy" [R-GA-1]
Earl
Carter
R
GA
L. "Buddy"
1
2023-01-17
True
- W000814
Rep. Weber, Randy K., Sr. [R-TX-14]
Randy
Weber
R
TX
K.
14
2023-01-17
True
- M001211
Rep. Miller, Mary E. [R-IL-15]
Mary
Miller
R
IL
E.
15
2023-01-17
True
- B001299
Rep. Banks, Jim [R-IN-3]
Jim
Banks
R
IN
3
2023-01-17
True
- J000304
Rep. Jackson, Ronny [R-TX-13]
Ronny
Jackson
R
TX
13
2023-01-17
True
- W000806
Rep. Webster, Daniel [R-FL-11]
Daniel
Webster
R
FL
11
2023-01-17
True
- D000615
Rep. Duncan, Jeff [R-SC-3]
Jeff
Duncan
R
SC
3
2023-01-17
True
- F000446
Rep. Feenstra, Randy [R-IA-4]
Randy
Feenstra
R
IA
4
2023-01-17
True
- S000522
Rep. Smith, Christopher H. [R-NJ-4]
CHRISTOPHER
SMITH
R
NJ
H.
4
2023-01-17
True
- G000565
Rep. Gosar, Paul A. [R-AZ-9]
Paul
Gosar
R
AZ
A.
9
2023-01-17
True
- S000250
Rep. Sessions, Pete [R-TX-17]
PETE
SESSIONS
R
TX
17
2023-01-24
False
- F000474
Rep. Flood, Mike [R-NE-1]
Mike
Flood
R
NE
1
2023-01-24
False
- G000576
Rep. Grothman, Glenn [R-WI-6]
Glenn
Grothman
R
WI
6
2023-01-24
False
- M001194
Rep. Moolenaar, John R. [R-MI-2]
John
Moolenaar
R
MI
R.
2
2023-01-24
False
- B000825
Rep. Boebert, Lauren [R-CO-3]
Lauren
Boebert
R
CO
3
2023-01-24
False
- M001199
Rep. Mast, Brian J. [R-FL-21]
Brian
Mast
R
FL
J.
21
2023-01-26
False
- G000594
Rep. Gonzales, Tony [R-TX-23]
Tony
Gonzales
R
TX
23
2023-01-26
False
- Y000067
Rep. Yakym, Rudy [R-IN-2]
Rudy
Yakym
R
IN
2
2023-01-26
False
- B001295
Rep. Bost, Mike [R-IL-12]
Mike
Bost
R
IL
12
2023-01-26
False
- G000591
Rep. Guest, Michael [R-MS-3]
Michael
Guest
R
MS
3
2023-02-06
False
- L000596
Rep. Luna, Anna Paulina [R-FL-13]
Anna Paulina
Luna
R
FL
13
2023-03-08
False
- H001077
Rep. Higgins, Clay [R-LA-3]
Clay
Higgins
R
LA
3
2023-03-17
False
- A000055
Rep. Aderholt, Robert B. [R-AL-4]
ROBERT
ADERHOLT
R
AL
B.
4
2023-08-11
False
Health
Health
2023-01-31T16:00:30Z
00
2023-01-17
Introduced in House
2023-05-26T18:41:32Z
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)
The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions.
In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers.
The bill nullifies the January 2023 changes and prohibits any similar changes in the future.

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
- Display Title
45

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
2024-06-12T18:20:59Z
- Official Title as Introduced
6

To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
2024-03-18T20:12:27Z
Introduced in House
IH
- Introduced in House
2023-01-17T05:00:00Z
  - https://www.govinfo.gov/content/pkg/BILLS-118hr383ih/xml/BILLS-118hr383ih.xml
2023-01-27
Referred to the Subcommittee on Health.
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
Congressional Research Service, Library of Congress
This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.